ArticleJournal of lipid research2012
Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity.
Article in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Cardiovascular safety in middle-aged and older men under testosterone replacement therapy: a systematic review and meta-analysis.Endocrine · 2026Pooled it
- Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy.Frontiers in endocrinology · 2022Trial
- Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.American journal of physiology. Endocrinology and metabolism · 2014Trial
- Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.Journal of clinical lipidologyTrial
- Serum testosterone and cardiometabolic risk in Nigerian men with type 2 diabetes: a cross-sectional study.Frontiers in endocrinology · 2026Article
- U-shaped association of uric acid to HDL cholesterol ratio (UHR) with ALL-cause and cardiovascular mortality in diabetic patients: NHANES 1999-2018.BMC cardiovascular disorders · 2024Article
- Changes in Blood Lipids Following Initiation of Gender Affirming Hormone Therapy: A Systematic Review and Meta-Analysis.Journal of clinical & translational endocrinology · 2024Article
- High-density lipoprotein (HDL) as an indicator for alcohol use in a psychiatrically ill population.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Observational
- Anabolic-androgenic steroids: How do they work and what are the risks?Frontiers in endocrinology · 2022Review
- Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.Reviews in endocrine & metabolic disorders · 2021Review
- Review
- Testosterone replacement therapy and cardiovascular risk.Nature reviews. Cardiology · 2019Review
- Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes.The Journal of clinical endocrinology and metabolism · 2014Article
- Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.International journal of clinical practice · 2014Observational
- HDL and cholesterol: life after the divorce?Journal of lipid research · 2014Review
- Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.Journal of lipid research · 2013Review
- Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis.Cholesterol · 2013Review
- Testosterone, HDL and cardiovascular risk in men: the jury is still out.Clinical lipidology · 2012Article
- An update on testosterone, HDL and cardiovascular risk in men.Clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
The effects of androgens on cardiovascular disease (CVD) risk in men remain unclear. To better characterize the relationship between androgens and HDL, we investigated the effects of testosterone replacement on HDL protein composition and serum HDL-mediated cholesterol efflux in hypogonadal men. Twenty-three older hypogonadal men (ages 51-83, baseline testosterone < 280 ng/dl) were administered replacement testosterone therapy (1% transdermal gel) with or without the 5α-reductase inhibitor dutasteride. At baseline and after three months of treatment, we determined fasting lipid concentrations, HDL protein composition, and the cholesterol efflux capacity of serum HDL. Testosterone replacement did not affect HDL cholesterol (HDL-C) concentrations but conferred significant increases in HDL-associated paraoxonase 1 (PON1) and fibrinogen α chain (FGA) (P = 0.022 and P = 0.023, respectively) and a decrease in apolipoprotein A-IV (apoA-IV) (P = 0.016). Exogenous testosterone did not affect the cholesterol efflux capacity of serum HDL. No differences were observed between men who received testosterone alone and those who also received dutasteride. Testosterone replacement in older hypogonadal men alters the protein composition of HDL but does not significantly change serum HDL-mediated cholesterol efflux. These effects appear independent of testosterone conversion to dihydrotestosterone. Further research is needed to determine how changes in HDL protein content affect CVD risk in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.